The profile of the patients referred by general practitioners to respiratory physicians for assessment of undiagnosed bronchial disease

被引:4
作者
Escamilla, R. [1 ]
Grignet, J. -P. [2 ]
Bourcereau, J. [3 ]
Mueser, M. [4 ]
机构
[1] Hop Larrey, Clin Voies Resp, F-31059 Toulouse 09, France
[2] CHG Denain, F-59723 Denain, France
[3] Hop Pr Seine St Denis, F-93150 Le Blanc Mesnil, France
[4] Boehringer Ingelheim GmbH & Co KG, F-75644 Paris, France
关键词
COPD; Asthma; Diagnosis; General practitioner; Obstruction; OBSTRUCTIVE PULMONARY-DISEASE; COPD; ASTHMA; FRANCE; CARE; POPULATION; IMPACT;
D O I
10.1016/j.rmr.2010.03.007
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction. - In general practice, COPD is often under-diagnosed and inappropriate pharmacological treatment given. Objectives. - To determine the profile of patients over 40 years old, smokers or ex-smokers, referred by general practitioners to respiratory physicians for assessment of undiagnosed bronchial disease. Methods. - Observational study carried-out among 103 respiratory physicians in France in 2007. Results. - The diagnosis of COPD was confirmed by the respiratory physicians in 433/486 (89%) patients. COPD patients were aged 61 years on average, male (63%) and often current smokers (46%). Most of them had more than three respiratory symptoms. The diagnosis of COPD was made after a long history of symptoms. We found 148 (34.2%) COPD patients with a FEV(1)/FVC greater than 0.7 and were classified as mild (61 patients), moderate (77 patients) or severe (10 patients). Conclusions. - In patients at risk, smokers or ex-smokers with respiratory symptoms, COPD was the diagnosis most often confirmed by the respiratory physician. A significant proportion of respiratory physicians diagnosed and assessed the severity of COPD, not strictly on the basis of national recommendations, but rather on the association of risk factors, respiratory symptoms and even isolated changes in FEV(1). (C) 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 22 条
[1]  
[Anonymous], 1995, Global Strategy for Asthma Management and Prevention
[2]  
[Anonymous], 2003, REV MAL RESPIR
[3]  
[Anonymous], PROGR ACT FAV BRONCH
[4]  
[Anonymous], 2016, Fact Sheet
[5]  
Bridevaux PO, 2008, THORAX, V63, P768, DOI 10.1136/thx.2007.093724
[6]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[7]   Corticosteroid reversibility in COPD is related to features of asthma [J].
Chanez, P ;
Vignola, AM ;
OShaugnessy, T ;
Enander, I ;
Li, DC ;
Jeffery, PK ;
Bousquet, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (05) :1529-1534
[8]   The SCOPE study: Health-care consumption related to patients with chronic obstructive pulmonary disease in France [J].
Detournay, B ;
Pribil, C ;
Fournier, M ;
Housset, B ;
Huchon, G ;
Huas, D ;
Godard, P ;
Voinet, C ;
Chanal, I ;
Jourdanne, C ;
Durand-Zaleski, I .
VALUE IN HEALTH, 2004, 7 (02) :168-174
[9]   Deaths from chronic obstructive pulmonary disease in France, 1979-2002: a multiple cause analysis [J].
Fuhrman, C. ;
Jougla, E. ;
Nicolau, J. ;
Eilstein, D. ;
Delmas, M-C .
THORAX, 2006, 61 (11) :930-934
[10]  
*INVS, 2008, BRONCH CHRON PREV IM